Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
American Journal of Cancer Research|December 18, 2018
Patients with RAS wild-type right-sided unresectable liver-confined mCRC also benefit from cetuximab plus chemotherapy in first-line treatmentPeng Zheng, Li Ren, Qingyang Feng, et al.
Elife|May 9, 2023
Proteomic characteristics reveal the signatures and the risks of T1 colorectal cancer metastasis to lymph nodesAojia Zhuang, Aobo Zhuang, Yijiao Chen, et al.
International Journal of Surgery (London, England)|August 1, 2023
Anatomical resection improves relapse-free survival in colorectal liver metastases in patients with KRAS/NRAS/BRAF mutations or right-sided colon cancer: a retrospective cohort studyWenju Chang, Yijiao Chen, Shizhao Zhou, et al.
Plos One|August 28, 2014
Determinants of long-term outcome in patients undergoing simultaneous resection of synchronous colorectal liver metastasesQi Lin, Qinghai Ye, Dexiang Zhu, et al.
International Journal of Oncology|February 6, 2016
Ribosomal protein S15A promotes malignant transformation and predicts poor outcome in colorectal cancer through misregulation of p53 signaling pathwayJingwen Chen, Ye Wei, Qingyang Feng, et al.
Cancer Management and Research|September 15, 2018
Differences in clinical characteristics and mutational pattern between synchronous and metachronous colorectal liver metastasesPeng Zheng, Li Ren, Qingyang Feng, et al.
Clinical Colorectal Cancer|June 7, 2024
VIC Regimen (Vemurafenib/Irinotecan/Cetuximab) Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Unresectable or Metastatic Colorectal Cancer in Asian Patients: A Prospective Cohort StudyYijiao Chen, Dexiang Zhu, Yiyi Yu, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 29, 2014
Aberrant expression of sphingosine-1-phosphate receptor 1 correlates with metachronous liver metastasis and poor prognosis in colorectal cancerQi Lin, Ye Wei, Yunshi Zhong, et al.
Annals of Surgery|October 15, 2015
Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon CancerWenju Chang, Ye Wei, Li Ren, et al.
Cancer Management and Research|October 2, 2018
Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancerYihao Mao, Qingyang Feng, Peng Zheng, et al.
Pageof 7